All of the Following Are True About Low-Molecular-Weight Heparin Therapy

All of the following are true about low-molecular-weight heparin therapy except:

A) It can be easier for both the physician and patient and therapeutic monitoring is not always required.
B) It can be given subcutaneously, and patients can administer it to themselves.
C) It is much less expensive than unfractionated heparin therapy and never causes HIT.
D) If monitoring is required, it cannot be monitored via the APTT.
E) It requires monitoring by a target concentration strategy.